IN2013CN00089A - - Google Patents

Info

Publication number
IN2013CN00089A
IN2013CN00089A IN89CHN2013A IN2013CN00089A IN 2013CN00089 A IN2013CN00089 A IN 2013CN00089A IN 89CHN2013 A IN89CHN2013 A IN 89CHN2013A IN 2013CN00089 A IN2013CN00089 A IN 2013CN00089A
Authority
IN
India
Prior art keywords
present
lactoferrin
wounds
fragments
lobe
Prior art date
Application number
Inventor
Benjamin David Ashby
Qian Garrett
Mark Willcox
Original Assignee
Holden Brien Vision Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010902932A external-priority patent/AU2010902932A0/en
Application filed by Holden Brien Vision Inst filed Critical Holden Brien Vision Inst
Publication of IN2013CN00089A publication Critical patent/IN2013CN00089A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to pharmaceutical compositions containing lactoferrin or fragments of it and their use in the treatment of wounds particularly corneal wounds. The present invention also provides a pharmaceutical composition comprising an effective amount of a polypeptide or peptidomimetic consisting essentially of the C lobe of lactoferrin or functionally active fragments or variants thereof.
IN89CHN2013 2010-07-01 2011-07-01 IN2013CN00089A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010902932A AU2010902932A0 (en) 2010-07-01 Lactoferrin sequences, compositions and methods of wound treatment
PCT/AU2011/000826 WO2012000054A1 (en) 2010-07-01 2011-07-01 Lactoferrin sequences, compositions and methods of corneal wound treatment

Publications (1)

Publication Number Publication Date
IN2013CN00089A true IN2013CN00089A (en) 2015-07-03

Family

ID=45401232

Family Applications (1)

Application Number Title Priority Date Filing Date
IN89CHN2013 IN2013CN00089A (en) 2010-07-01 2011-07-01

Country Status (10)

Country Link
US (1) US20130101575A1 (en)
EP (1) EP2588128A4 (en)
JP (1) JP2013530990A (en)
CN (1) CN103037894A (en)
AU (1) AU2011274244A1 (en)
CA (1) CA2803932A1 (en)
IN (1) IN2013CN00089A (en)
SG (1) SG186841A1 (en)
TW (1) TW201204384A (en)
WO (1) WO2012000054A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110606A1 (en) * 2011-11-16 2013-05-17 Ist Superiore Sanita LATTOFERRINA PEPTIDES FOR USE AS HIGH-SPECIMEN INHIBITORS OF VIRUS INFLUENCE INFECTION.
US11376311B2 (en) 2017-11-02 2022-07-05 Colorado Seminary, Owner and Operator of University of Denver Methods of treating microbial infection and inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148631T1 (en) * 1990-11-13 1997-02-15 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR CORNEAL INJURIES
EP2298338B1 (en) * 2002-09-16 2012-08-22 Agennix Incorporated Lactoferrin compositions and methods of treatment of skin wounds
CA2587727A1 (en) * 2004-11-19 2006-05-26 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
EP1937298A4 (en) * 2005-10-14 2009-11-11 Auckland Uniservices Ltd Use of lactoferrin fragments and hydrolysates
NZ552316A (en) * 2006-12-22 2009-10-30 Fonterra Co Operative Group Dairy product and process

Also Published As

Publication number Publication date
US20130101575A1 (en) 2013-04-25
JP2013530990A (en) 2013-08-01
TW201204384A (en) 2012-02-01
WO2012000054A1 (en) 2012-01-05
EP2588128A1 (en) 2013-05-08
SG186841A1 (en) 2013-02-28
EP2588128A4 (en) 2014-03-19
CA2803932A1 (en) 2012-01-05
CN103037894A (en) 2013-04-10
AU2011274244A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
EP2528934A4 (en) Aromatic-cationic peptides and uses of same
EP2575884A4 (en) Uses and compositions for treatment of hidradenitis suppurativa (hs)
MX2014001050A (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate.
NZ727516A (en) Treatment of ocular neovascularization using a recombinant virus containing a nucleic acid encoding a vegf inhibitor
MX2014001372A (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
IN2014KN02830A (en)
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
IN2013CN01340A (en)
WO2013186777A3 (en) Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
CO6710913A2 (en) Use of lysosomal lipase acid to treat lysosomal lipase acid deficiency in patients
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
MX2012013606A (en) Tamarind seed polysaccharide for use in the treatment of microbial infections.
MX2009000359A (en) Methods for treating and limiting fibrotic disorders and keloids.
SG10201406288SA (en) Multimeric forms of antimicrobial peptides
WO2015157469A3 (en) Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing
EP2490700A4 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MX341020B (en) Human lactoferrin derived peptides and there use.
GEP201606514B (en) Apoptosis inhibitors and usage thereof
EP2438923A4 (en) Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients
MX2013002118A (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
MX2011007462A (en) Hylauronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation.
BR112015011693A2 (en) fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebotrombotic conditions
IN2013CN00089A (en)